And the tease works just as well when watching sport, a generally disappointing activity that costs time, money, energy and patience.
She added that Ticketmaster officials, who have waived the company's normal fees to support the concert, "whole-heartedly applaud Senator Schumer for drawing attention to the disappointing activity on the secondary market".
The current combination of gemcitabine and vindesine does not appear to be promising for further examination because of the toxicity and somewhat disappointing activity.
In our investigation, compounds 4 (C(5)-SO2NH2), 5 (C(5)-SO2NMe2), 6 (C(5)-SO2NEt2), 8 (C 5 -SO2NHPh), and 9 (C 5 -SO2NH 4-CF3-Ph C 5 -SO2NH 4-CF3-Ph C 5 -SO2NH 4-CF3-Ph C 5 -SO2NH 4-CF3-Phent in VEGFR-2 inhibition; however, 7 (C(5)-showedH2CH2Cl)2) disappointingdent improvement.
According to the authors, although the results of the screening (some of them reported in Table 1, entry 7) are quite disappointing, biological activity resulted higher than that of the same compounds with a phenyl group instead of the ferrocenyl one.
Our results suggest the disappointing clinical activity of single-agent rapamycin analogs in PTEN-deficient human cancers, as compared to single-lesion transgenic mouse models, may arise from secondary genetic alterations in human tumors.
In a recent study, published in abstract form (McDermott et al, 2011) capecitabine in combination with lapatinib, a small molecule, tyrosine kinase inhibitor of epidermal growth factor receptor and HER2 showed disappointing antitumour activity with an OS of 4 months.
Overall, our data support the hypothesis that IR activation by IGF-2 may account for the failure of IGF-1R only-targeting agents to suppress TNBC cell migration in vitro, suggesting that it may also be involved in the disappointing clinical activity exhibited by such agents.
Lower down the market, insulation specialist Superglass dropped 4p to 5.25p after it warned trading since its last update in February had been disappointing, with construction activity hampered by the bad weather.
In light of the relatively disappointing single agent activity of rapalogs in prostate cancer, it may be critical to assess the MYC status of prostate tumors (among several other markers) to guide the interpretation of response data in patients undergoing PI3K inhibitor therapy.
Although the major phase 3 trials with cediranib have produced disappointing results, promising activity has been seen with cediranib monotherapy in ovarian cancer (Hirte et al, 2008; Matulonis et al, 2009).
